Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

Yoshinobu Kanda · Bone Marrow Transplantation · 2012 · 18.7K citations

Public Health, Biostatistics, Hematology +11

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text

Medicine, Oncology, Metastasis +5

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Jan B. Vermorken, Fernando Rivera, Éva Remenár et al. · New England Journal of Medicine · 2008 · 3.7K citations · Full text

Medicine, Oncology, Pharmacology +16

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Alexander C. Huang, Michael A. Postow, Robert J. Orlowski et al. · Nature · 2017 · 1.7K citations · Full text

Life Sciences, Immunology, Oncology +16